Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline ...

The annual Santa Barbara Great Strides walk is a step around the corner and participating teams have already entered the race ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...

The projected market expansion presents a unique opportunity for stakeholders to invest in and prioritize the development of ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...